Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Pharm Pharm Sci. 2013;16(1):74-88.

Efficacy and toxicity of factor Xa inhibitors.

Author information

  • 1Assistance Publique-Hôpitaux de Marseille, Service de la Pharmacie à Usage Intérieur de l'Hôpital Nord,Marseille, France.

Abstract

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists).

PMID:
23683607
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Canadian Society for Pharmaceutical Sciences
    Loading ...
    Write to the Help Desk